For the purpose of this study, the various products studied includes consumables and reagents, and instruments. The process are classified as upstream and downstream.

Based on molecule type, this market is further segmented as monoclonal antibodies, vaccines, recombinant insulin, human growth hormones and others. Market size estimates and forecast of these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The geographic segmentation of the global high throughput process development market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa.

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global high throughput process development market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global high throughput process development market. The major players in high throughput process development market are Agilent Technologies, Inc., Axxam S.P.A., Aurora Biomed, Bio-Rad Laboratories, Inc., Danaher Corporation, Hamilton Company, Merck Millipore Corporation, Perkin Elmer, Inc., Tecan Group Ltd., Thermo Fisher Scientific, Inc.

High throughput process development is of prime importance as there is tantamount requirement of a robust, reproducible manufacturing process in the life science industries as it is a critical pathway for the development of novel therapies. In order to meet regulatory requirements and technical challenges, a very good understanding of the critical processes and multiparameters involved in high throughput process development is mandatory. In 2016, monoclonal antibodies segment dominated the market mainly due to factors such as rising adoption of targeted immunotherapy, they are highly reproducible, scalable and unlimited production source and hybridomas serve as an immortal source for the production of monoclonal antibodies. The limitations of monoclonal antibodies is that the system is well developed for only mouse and rat models and not for other animals and the USFDA stipulates that monoclonal antibodies are intended for human purpose should be totally free from pathogens including viruses. The vaccines segment is anticipated to register faster growth throughout the forecast period 2017-2025, majorly due to rising incidence of contagious diseases spread by vectors such as parasities, bacteria and virus and they are helpful in preventing the greater cost incurred during the treatment of infectious disease.

In the current regulatory scenario, it often takes around a decade and huge amount of money to promote a drug candidate from the development process to the shelves. There is a strong impetus for pursuing methodologies, which can shorten this gap in the process development and manufacturing. In 2016, upstream segment held the largest market share chiefly due to factors such as technological advancement in the production and development of biological drugs has built a strong impetus from novel bio therapeutics clinical trials, optimization of growth kinetics for the enhanced product development and improvement in the inoculum by genetic engineering.

Downstream will be the fastest growing segment throughout the forecast period 2017-2025. Factors supporting the growth of this segment include technological advancement in the separation of biomass from the fermented broth by the centrifugation and ultracentrifugation techniques and stringent regulatory guidelines stipulated by the USFDA, making it extremely important for effective purification of active metabolites as there have been several incidents reported regarding biological drugs related serious adverse events.

The high throughput process development market is driven by factors such as rising prevalence of chronic diseases, aging population and burgeoning requirement for launch of novel drugs to counteract the multiple drug resistance bacterial infection. In addition, increasing number of diagnostic centers and growing physician awareness regarding disease etiology will propel the market penetration for high throughput screening. In 2016, instruments segment held the largest market share chiefly due to factors such as technological advancement in automation techniques and huge application in biopharmaceuticals, contract research organizations, and research institutes etc.

Consumables and reagents will be the fastest growing segment throughout the forecast period 2017-2025 majorly due to factors such as rising prevalence of chronic diseases, steadily increasing diagnostic centers and public private partnership to combat life threatening diseases by setting research and development centers. The major players in high throughput screening market are Agilent Technologies, Inc., Axxam S.P.A., Aurora Biomed, Bio-Rad Laboratories, Inc., Danaher Corporation, Hamilton Company, Merck Millipore Corporation, Perkin Elmer, Inc., Tecan Group Ltd., Thermo Fisher Scientific, Inc.

North America was observed to be the largest market for high throughput process development in the base year 2016. The dominance of North America is mainly attributed to the presence of major giants in biotechnology and pharmaceutical industries focusing on novel drug discovery of biological drug candidates, and existence of advanced healthcare and research facilities. The market growth in Europe is mainly attributed to the increasing number of patients suffering with chronic diseases. This factor boosts the demand for lowering the manufacturing cost of biological drugs and reducing the product development timelines. Asia Pacific was observed as the fastest growing regional segment throughout the forecast period 2017-2025. Factors that are anticipated to propel the market growth in Asia Pacific are presence of large patient pool which can be enrolled to study the safety and efficacy studies for biological drug candidates during clinical trials and enhanced research and development spending by the governmental organizations. Moreover, factors such as developing healthcare infrastructure, and public private partnership between major biopharmaceutical players and academic research institutes are going to fuel the rapid growth of high throughput process development market in Latin America, and Middle East and Africa in the near future.   

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of High Throughput Process Development market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the High Throughput Process Development market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of High Throughput Process Development market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the High Throughput Process Development market?
• Which is the largest regional market for High Throughput Process Development market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving High Throughput Process Development market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the High Throughput Process Development market worldwide?